Patents Assigned to Berlex Laboratories, Inc.
  • Human interferon-.beta. (IFN-.beta.) produced in Chinese hamster ovary (CHO) cells
    Patent number: 5795779
    Abstract: .beta.-interferon is produced in Chinese hamster ovary cells (CHO) in high amounts.
    Type: Grant
    Filed: August 12, 1994
    Date of Patent: August 18, 1998
    Assignees: Berlex Laboratories, Inc., Leland Stanford Junior University
    Inventors: Francis P. McCormick, Michael A. Innis, Gordon M. Ringold
  • Purine derivatives and their use as anti-coagulants
    Patent number: 5753635
    Abstract: This invention is directed to purine derivatives of the following formulae: ##STR1## wherein Z.sup.1 is --O--, --N(R.sup.10)-- or --CH.sub.2 O--;Z.sup.2 is --O--, --N(R.sup.10)-- or --OCH.sub.2 --;R.sup.1 and R.sup.4 are each independently hydrogen, halo, alkyl, --OR.sup.10, --C(O)OR.sup.10, --C(O)N(R.sup.10)R.sup.11, --N(R.sup.10)R.sup.11, --N(R.sup.10)C(O)R.sup.10, or --N(H)S(O).sub.2 R.sup.13 ;R.sup.2 is --C(NH)NH.sub.2, --C(NH)N(H)OR.sup.10, --C(NH)N(H)C(O)OR.sup.13, --C(NH)N(H)C(O)R.sup.10, --C(NH)N(H)S(O).sub.2 R.sup.13, or --C(NH)N(H)C(O)N(H)R.sup.10 ;R.sup.3 is halo, alkyl, haloalkyl, haloalkoxy, ureido, cyano, guanidino, --OR.sup.10, --C(NH)NH.sub.2, --C(NH)N(H)OR.sup.10, --C(O)N(R.sup.10)R.sup.11, --R.sup.12 --C(O)N(R.sup.10)R.sup.11, --CH(OH)C(O)N(R.sup.10)R.sup.11, --N(R.sup.10)R.sup.11, --R.sup.12 --N(R.sup.10)R.sup.11, --C(O)OR.sup.10, --R.sup.12 --C(O)OR.sup.10, --N(R.sup.10)C(O)R.sup.
    Type: Grant
    Filed: August 16, 1996
    Date of Patent: May 19, 1998
    Assignee: Berlex Laboratories, Inc.
    Inventors: Brad O. Buckman, Raju Mohan, Michael M. Morrissey
  • N,N-di(aryl) cyclic urea derivatives as anti-coagulants
    Patent number: 5731308
    Abstract: N,N-di(aryl) cyclic urea derivatives, such as the compounds of the following formula: ##STR1## wherein R.sup.1 is --C(NH)NH.sub.2, --C(NH)N(H)OR.sup.11, --C(NH)N(H)C(O)R.sup.9, or --C(NH)N(H)C(O)OR.sup.11 ;R.sup.2 and R.sup.3 are independently hydrogen, halo, lower alkyl, lower haloalkyl, aryl, --OR.sup.11, --C(O)OR.sup.11, --C(O)N(R.sup.11)R.sup.12, --N(R.sup.11)R.sup.12, --N(H)C(O)R.sup.11, or --N(H)S(O).sub.2 R.sup.11 ;R.sup.4 is halo, lower haloalkyl, imidazolyl, --C (NH)NH.sub.2, --C(NH)NHOR.sup.11, --C(NH)N(H)C(O)R.sup.9, --C(NH)N(H)C(O)OR.sup.11, --OR.sup.11, --C(O)R.sup.13, --(CH.sub.2).sub.n C(O)OR.sup.11 (where n is 0 to 6), --C(O)N(R.sup.11)R.sup.12, or --N(R.sup.11)R.sup.12 ;R.sup.7 and R.sup.8 are independently hydrogen, lower alkyl, lower haloalkyl, 4-pyridinyl, --C(O)OR.sup.11, --C(O)N(R.sup.11)R.sup.12, or aryl (optionally substituted by one or more substituents selected from the group consisting of halo, hydroxy, lower alkyl, lower haloalkyl, lower alkoxy and --N(R.sup.11)R.sup.12);R.sup.
    Type: Grant
    Filed: December 12, 1996
    Date of Patent: March 24, 1998
    Assignee: Berlex Laboratories, Inc.
    Inventors: Raju Mohan, Michael M. Morrissey
  • N,N-di(aryl) cyclic urea derivatives as anti-coagulants
    Patent number: 5731311
    Abstract: N,N-di(aryl) cyclic urea derivatives, such as the compounds of the following formula: ##STR1## wherein R.sup.1 is --C(NH)NH.sub.2, --C(NH)N(H)OR.sup.11, --C(NH)N(H)C(O)R.sup.9, or --C(NH)N(H)C(O)OR.sup.11 ;R.sup.2 and R.sup.3 are independently hydrogen, halo, lower alkyl, lower haloalkyl, aryl, --OR.sup.11, --C(O)OR.sup.11, --C(O)N(R.sup.11)R.sup.12, --N(R.sup.11)R.sup.12, --N(H)C(O)R.sup.11, or --N(H)S(O).sub.2 R.sup.11 ;R.sup.4 is halo, lower haloalkyl, imidazolyl, --C(NH)NH.sub.2, --C(NH)NHOR.sup.11, --C(NH)N(H)C(O)R.sup.9, --C(NH)N(H)C(O)OR.sup.11, --OR.sup.11, --C(O)R.sup.13, --(CH.sub.2).sub.n C(O)OR.sup.11 (where n is 0 to 6), --C(O)N(R.sup.11)R.sup.12, or --N(R.sup.11)R.sup.12 ;R.sup.7 and R.sup.8 are independently hydrogen, lower alkyl, lower haloalkyl, 4-pyridinyl, --C(O)OR.sup.11, --C(O)N(R.sup.11)R.sup.12, or aryl (optionally substituted by one or more substituents selected from the group consisting of halo, hydroxy, lower alkyl, lower haloalkyl, lower alkoxy and --N(R.sup.11)R.sup.12);R.sup.
    Type: Grant
    Filed: December 12, 1996
    Date of Patent: March 24, 1998
    Assignee: Berlex Laboratories, Inc.
    Inventors: Raju Mohan, Michael M. Morrissey
  • N,N-di(aryl) cyclic urea derivatives as anti-coagulants
    Patent number: 5728697
    Abstract: N,N-di(aryl) cyclic urea derivatives, such as the compounds of the following formula: ##STR1## wherein R.sup.1 is --C(NH)NH.sub.2, --C(NH)N(H)OR.sup.11, --C(NH)N(H)C(O)R.sup.9, or --C(NH)N(H)C(O)OR.sup.11 ;R.sup.2 and R.sup.3 are independently hydrogen, halo, lower alkyl, lower haloalkyl, aryl, --OR.sup.11, --C(O)OR.sup.11, --C(O)N(R.sup.11)R.sup.12, --N(R.sup.11)R.sup.12, --N(H)C(O)R.sup.11, or --N(H)S(O).sub.2 R.sup.11 ;R.sup.4 is halo, lower haloalkyl, imidazolyl, --C(NH)NH.sub.2, --C(NH)NHOR.sup.11, --(CH.sub.2).sub.n C(O)OR.sup.11 (where n is 0 to 6), --C(O)N(R.sup.11)R.sup.12, or --N(R.sup.11)R.sup.12 ;R.sup.7 and R.sup.8 are independently hydrogen, lower alkyl, lower haloalkyl, 4-pyridinyl, --C(O)OR.sup.11, --C(O)N(R.sup.11)R.sup.12, or aryl (optionally substituted by one or more substituents selected from the group consisting of halo, hydroxy, lower alkyl, lower haloalkyl, lower alkoxy and --N(R.sup.11)R.sup.12);R.sup.11 and R.sup.12 are independently hydrogen, lower alkyl, aryl or lower aralkyl; orR.
    Type: Grant
    Filed: December 12, 1996
    Date of Patent: March 17, 1998
    Assignee: Berlex Laboratories, Inc.
    Inventors: Raju Mohan, Michael M. Morrissey
  • N.N-di (aryl) cyclic urea derivatives as anti-coagulants
    Patent number: 5726173
    Abstract: N,N-di(aryl) cyclic urea derivatives, such as the compounds of the following formula: ##STR1## wherein R.sup.1 is --C(NH)NH.sub.2, --C(NH)N(H)OR.sup.11, --C(NH)N(H)C(O)R.sup.9, or --C(NH)N(H)C(O)OR.sup.11 ;R.sup.2 and R.sup.3 are independently hydrogen, halo, lower alkyl, lower haloalkyl, aryl, --OR.sup.11, --C(O)OR.sup.11, --C(O)N(R.sup.11)R.sup.12, --N(R.sup.11)R.sup.12, --N(H)C(O)R.sup.11, or --N(H)S(O).sub.2 R.sup.11 ;R.sup.4 is halo, lower haloalkyl, imidazolyl, --C(NH)NH.sub.2, --C(NH)NHOR.sup.11, --C(NH)N(H)C(O)R.sup.9, --C(NH)N(H)C(O)OR.sup.11, --OR.sup.11, --C(O)R.sup.13, --(CH.sub.2).sub.n C(O)OR.sup.11 (where n is 0 to 6), --C(O)N(R.sup.11)R.sup.12, or --N(R.sup.11)R.sup.12 ;R.sup.7 and R.sup.8 are independently hydrogen, lower alkyl, lower haloalkyl, 4-pyridinyl, --C(O)OR.sup.11, --C(O)N(R.sup.11)R.sup.12, or aryl (optionally substituted by one or more substituents selected from the group consisting of halo, hydroxy, lower alkyl, lower haloalkyl, lower alkoxy and --N(R.sup.11)R.sup.12);R.sup.
    Type: Grant
    Filed: December 12, 1996
    Date of Patent: March 10, 1998
    Assignee: Berlex Laboratories, Inc.
    Inventors: Raju Mohan, Michael M. Morrissey
  • N,N-di(aryl) cyclic urea derivatives as anti-coagulants
    Patent number: 5726198
    Abstract: N,N-di(aryl) cyclic urea derivatives, such as the compounds of the following formula: ##STR1## wherein R.sup.1 is --C(NH)NH.sub.2, --C(NH)N(H)OR.sup.11, --C(NH)N(H)C(O)R.sup.9, or --C(NH)N(H)C(O)OR.sup.11 ;R.sup.2 and R.sup.3 are independently hydrogen, halo, lower alkyl, lower haloalkyl, aryl, --OR.sup.11, --C(O)OR.sup.11, --C(O)N(R.sup.11)R.sup.12, --N(R.sup.11)R.sup.12, --N(H)C(O)R.sup.11, or --N(H)S(O).sub.2 R.sup.11 ;R.sup.4 is halo, lower haloalkyl, imidazolyl, --C(NH)NH.sub.2, --C(NH)NHOR.sup.11, --C(NH)N(H)C(O)R.sup.9, --C(NH)N(H)C(O)OR.sup.11, --OR.sup.11, --C(O)R.sup.13, --(CH.sub.2).sub.n C(O)OR.sup.11 (where n is 0 to 6), --C(O)N(R.sup.11)R.sup.12, or --N(R.sup.11)R.sup.12 ;R.sup.7 and R.sup.8 are independently hydrogen, lower alkyl, lower haloalkyl, 4-pyridinyl, --C(O)OR.sup.11, --C(O)N(R.sup.11)R.sup.12, or aryl (optionally substituted by one or more substituents selected from the group consisting of halo, hydroxy, lower alkyl, lower haloalkyl, lower alkoxy and --N(R.sup.11)R.sup.12);R.sup.
    Type: Grant
    Filed: December 12, 1996
    Date of Patent: March 10, 1998
    Assignee: Berlex Laboratories, Inc.
    Inventors: Raju Mohan, Michael M. Morrissey
  • Mutagenesis methods and compositions
    Patent number: 5702931
    Abstract: Methods and reagents for oligonucleotide-directed mutagenesis of a target nucleic acid are provided. In these methods a mutagenic oligonucleotide introduces a desired mutation at one site and, at a second site, introduces or eliminates a restriction site, allowing one to screen for the desired mutation by restriction analysis. Also provided are vectors and kits for performing such mutagenesis methods.
    Type: Grant
    Filed: December 28, 1993
    Date of Patent: December 30, 1997
    Assignee: Berlex Laboratories, Inc.
    Inventors: William H. Andrews, Michael J. Morser, Laura R. Vilander
  • Bicyclic pyrimidine derivatives and their use as anti-coagulants
    Patent number: 5693641
    Abstract: This invention is directed to bicyclic pyrimidine derivatives which are useful as anti-coagulants. This invention is also directed to pharmaceutical compositions containing the compounds of the invention, and methods of using the compounds to treat disease-states characterized by thrombotic activity.
    Type: Grant
    Filed: August 16, 1996
    Date of Patent: December 2, 1997
    Assignee: Berlex Laboratories Inc.
    Inventors: Brad O. Buckman, Raju Mohan, Michael M. Morrissey
  • Benzamidine derivatives and their use as anti-coagulants
    Patent number: 5691364
    Abstract: This invention is directed to benzamidine derivatives which are useful as anti-coagulants. This invention is also directed to pharmaceutical compositions containing the compounds of the invention, and methods of using the compounds to treat disease-states characterized by thrombotic activity.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 25, 1997
    Assignee: Berlex Laboratories, Inc.
    Inventors: Brad O. Buckman, David D. Davey, William J. Guilford, Michael M. Morrissey, Howard P. Ng, Gary B. Phillips, Shung C. Wu, Wei Xu
  • Method of using beta-interferons to treat restenosis
    Patent number: 5681558
    Abstract: The use of human interferon-.beta. to treat or prevent coronary restenosis is described herein.
    Type: Grant
    Filed: November 30, 1995
    Date of Patent: October 28, 1997
    Assignee: Berlex Laboratories, Inc.
    Inventors: Anthony Johns, Robert J. Mintzer
  • Treatment of multiple sclerosis
    Patent number: 5672622
    Abstract: The present invention is a method of preventing or ameliorating the episodic recurrence of MS, comprising administering an effective amount of selective phosphodiesterase inhibitors of Type IV, e.g., Rolipram, e.g., wherein the severity of the episodic recurrences is ameliorated or the time period between episodes is lengthened.
    Type: Grant
    Filed: October 21, 1994
    Date of Patent: September 30, 1997
    Assignee: Berlex Laboratories, Inc.
    Inventors: Joseph Hedgepeth, Helmut Wachtel
  • Vial holder
    Patent number: 5669502
    Abstract: A vial holder is provided which is easily loaded with a vial, retains the vial in a rigid manner and permits the vial to be discharged in a simple manner. The vial holder can also exhibit two vial retention sections for simultaneously rigidly holding two vials.
    Type: Grant
    Filed: April 17, 1995
    Date of Patent: September 23, 1997
    Assignee: Berlex Laboratories, Inc.
    Inventors: Holly Ong, Paul Schmid, Cliff Wood, David G. Bragin
  • (Z,Z), (Z,E) and (E,Z) isomers of substituted bis(phenylmethylene)cycloketones
    Patent number: 5633381
    Abstract: This invention relates to novel (Z,Z), (Z,E) and (E,Z) olefin isomers of substituted benzylidene cycloketones and their pharmaceutically acceptable salts. The compounds of the invention are potent factor Xa inhibitors thereby acting as anticoagulants useful in a number of thrombotic disease states. Pharmaceutical compositions are proposed for the compounds.
    Type: Grant
    Filed: July 5, 1994
    Date of Patent: May 27, 1997
    Assignee: Berlex Laboratories, Inc.
    Inventors: Jerry L. Dallas, William J. Guilford, Sunil K. Koovakkat, Michael M. Morrissey, Kenneth J. Shaw
  • N,N-di(aryl) cyclic urea derivatives as anti-coagulants
    Patent number: 5612363
    Abstract: N,N-di(aryl) cyclic urea derivatives, such as the compounds of the following formula: ##STR1## wherein R.sup.1 is --C(NH)NH.sub.2, --C(NH)N(H)OR.sup.11, --C(NH)N(H)C(O)R.sup.9, or --C(NH)N(H)C(O)OR.sup.11 ;R.sup.2 and R.sup.3 are independently hydrogen, halo, lower alkyl, lower haloalkyl, aryl, --OR.sup.11, --C(O)OR.sup.11, --C(O)N(R.sup.11)R.sup.12, --N(R.sup.11)R.sup.12, --N(H)C(O)R.sup.11, or --N(H)S(O).sub.2 R.sup.11 ;R.sup.4 is halo, lower haloalkyl, imidazolyl, --C(NH)NH.sub.2, --C(NH)NHOR.sup.11, --C(NH)N(H)C(O)R.sup.9, --C(NH)N(H)C(O)OR.sup.11, --OR.sup.11, --C(O)R.sup.13, --(CH.sub.2).sub.n C(O)OR.sup.11 (where n is 0 to 6), --C(O)N(R.sup.11)R.sup.12, or --N(R.sup.11)R.sup.12 ;R.sup.7 and R.sup.8 are independently hydrogen, lower alkyl, lower haloalkyl, 4-pyridinyl, --C(O)OR.sup.11, --C(O)N(R.sup.11)R.sup.12, or aryl (optionally substituted by one or more substituents selected from the group consisting of halo, hydroxy, lower alkyl, lower haloalkyl, lower alkoxy and --N(R.sup.11 R.sup.12);R.sup.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: March 18, 1997
    Assignee: Berlex Laboratories, Inc.
    Inventors: Raju Mohan, Michael M. Morrissey
  • Tricyclic pteridinones and a process for their preparation
    Patent number: 5602252
    Abstract: This invention relates to novel tricyclic pteridinones, their aza analogs and their pharmaceutically acceptable salts. Further encompassed by the invention is a novel process for the production of the tricyclic pteridinones and their aza analogs. The compounds of the invention exhibit cardiovascular properties, particularly mixed vasodilation and selective venous and arterial dilation. Pharmaceutical compositions are proposed for the compounds.
    Type: Grant
    Filed: February 8, 1994
    Date of Patent: February 11, 1997
    Assignee: Berlex Laboratories, Inc.
    Inventor: David D. Davey
  • Solubilization and purification of the active gastrin releasing peptide receptor
    Patent number: 5591831
    Abstract: A procedure for the preparation of the solubilized and purified gastrin releasing peptide receptor, in an active form, from a gastrin releasing peptide receptor source such as Swiss 3T3 fibroblasts.
    Type: Grant
    Filed: January 25, 1994
    Date of Patent: January 7, 1997
    Assignee: Berlex Laboratories, Inc.
    Inventors: Richard I. Feldman, James M. Wu, Elaina Mann, Anne Larocca, James C. Jenson
  • Topical bioadhesive ointment compositions and their use in wound healing
    Patent number: 5578310
    Abstract: A topical bioadhesive ointment composition comprising an aqueous mineral oil emulsion which is readily spread able and film-forming, and, upon application to moist skin or a mucosal surface, forms a stable, coherent layer thereon which resists removal therefrom by water or a body fluid associated with the mucosal surface to which the ointment composition is applied is disclosed. Also disclosed are pharmaceutical compositions containing the ointment compositions and a pharmaceutically active agent, e.g. , TGF.alpha.; and methods of using and methods of preparing the compositions.
    Type: Grant
    Filed: June 3, 1994
    Date of Patent: November 26, 1996
    Assignee: Berlex Laboratories Inc.
    Inventors: Thabiso M'Timkulu, Ze'ev Shaked, Richard Hsu
  • Polyamides bearing functionalized side chains useful as water soluble hypolipidemic agents
    Patent number: 5516758
    Abstract: This invention relates to derivatives of polyanhydroaspartic acid which are non-systemic water soluble polymers and which are intended to be lipid lowering agents. The pharmaceutical compositions/formulations incorporating these compounds are also discussed.
    Type: Grant
    Filed: December 23, 1993
    Date of Patent: May 14, 1996
    Assignee: Berlex Laboratories, Inc.
    Inventors: Kent R. Stevens, William V. Taggart
  • Inhibitors of the conversion of big endothelin to endothelin
    Patent number: 5504070
    Abstract: Novel and known compounds are described which inhibit endothelin converting enzyme (ECE), thereby preventing the conversion of Big Endothelin (BET) to Endothelin (ET). Pharmaceutical usefulness and preparations are described.
    Type: Grant
    Filed: December 5, 1991
    Date of Patent: April 2, 1996
    Assignee: Berlex Laboratories, Inc.
    Inventors: Ron H. Bihovsky, Paul W. Erhardt, John W. Lampe, Raju Mohan, Kenneth J. Shaw